Vireo Growth (VREOF) Deferred Taxes (2020 - 2026)

Vireo Growth (VREOF) posted Deferred Taxes of $2.2 million for Q1 2026, down 4.76% sequentially from $2.3 million in Q4 2023.

Vireo Growth (VREOF) Deferred Taxes (2020 - 2026) Analysis & Trends

Vireo Growth has reported Deferred Taxes for 5 years, with the latest figure at $2.2 million in Q1 2026.

Quarterly Deferred Taxes changed N/A year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (changed N/A YoY) and the FY2025 annual result came in at $13.4 million, changed N/A from the prior year.
Deferred Taxes eased to $2.2 million in Q1 2026 per VREOF's latest filing, from $2.3 million in the prior quarter.
Over five years, Deferred Taxes peaked at $4.0 million in Q4 2022 and troughed at -$3.1 million in Q1 2022.
A 3-year average of $410555.6 and a median of -$60000.0 in 2023 frame the typical range for Deferred Taxes.
The widest YoY moves for Deferred Taxes: up 444.82% in 2022, down 3933.33% in 2022.
Over 3 years, Deferred Taxes stood at $4.0 million in 2022, then slumped by 42.15% to $2.3 million in 2023, then slipped by 4.76% to $2.2 million in 2026.
According to Business Quant data, Deferred Taxes over the past three periods registered $2.2 million, $2.3 million, and -$500000.0 for Q1 2026, Q4 2023, and Q3 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn	25.00 Mn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn	-33.00 Mn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn	-
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn	25.70 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	-124.50 Mn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn	-25.30 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Vireo Growth	487.39 Mn	345.09 Mn	95.30 Mn	-5.70 Mn

Download Data